Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject in need thereof, a therapeutically effective amount of azaquinone or a pharmaceutical composition consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions comprising a therapeutically effective amount of azaquinone or consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject in need thereof, a therapeutically effective amount of azaquinone or a pharmaceutical composition consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions comprising a therapeutically effective amount of azaquinone or consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprise administering to the subject in need thereof a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a clofazimine analog selected from B746 clofazimine analog or B826 clofazimine analog.

Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject a pharmaceutical composition consisting of clofazimine and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions consisting of clofazimine at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.

Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of clofazimine and/or a clofazimine analogue. Pharmaceutical compositions comprising clofazimine and/or an analogue(s) thereof, and optionally one or more additional therapeutic agents, are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.